New drug trial offers hope for Tough-to-Treat lung cancer
NCT ID NCT06095505
Summary
This study is testing an oral drug called alisertib for people with advanced small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. The main goal is to see if the drug can shrink tumors and control the cancer's growth, and to identify which patients might benefit most based on their tumor biology. Researchers will also closely monitor the drug's safety and how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Clermont Oncology Center
RECRUITINGClermont, Florida, 64711, United States
-
Cleveland Clinic
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Georgetown Lombardi Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20057, United States
-
Henry Ford Hospital
RECRUITINGDetroit, Michigan, 48202, United States
-
Illinois Cancer Specialists
RECRUITINGNiles, Illinois, 60714, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Marshfield Medical Center
RECRUITINGMarshfield, Wisconsin, 54449, United States
-
Medical University of South Carolina Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
-
Minnesota Oncology Hematology
RECRUITINGBurnsville, Minnesota, 55337, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Nebraska Cancer Specialists
RECRUITINGGrand Island, Nebraska, 68803, United States
-
Northwest Cancer Specialists
RECRUITINGVancouver, Washington, 98686, United States
-
Oncology & Hematology Associates of Southwest Virginia
RECRUITINGBlacksburg, Virginia, 24073, United States
-
Oncology Associates of Oregon
RECRUITINGEugene, Oregon, 97401, United States
-
Oncology Hematology Care Clinical Trials
RECRUITINGCincinnati, Ohio, 45226, United States
-
Rocky Mountain Cancer Centers
RECRUITINGLone Tree, Colorado, 80124, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Southern Cancer Center
RECRUITINGDaphne, Alabama, 36526, United States
-
Texas Oncology-Baylor Charles A. Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
-
The Oncology Institute of Hope and Innovation
RECRUITINGLong Beach, California, 90805, United States
-
The Oncology Institute of Hope and Innovation
RECRUITINGFort Lauderdale, Florida, 33316, United States
-
UPMC Hillman Cancer Center
WITHDRAWNPittsburgh, Pennsylvania, 15232, United States
-
University Hospital - Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
Universtity of Virginia Health System
COMPLETEDCharlottesville, Virginia, 22908, United States
-
Virginia Cancer Specialists Research Institute
RECRUITINGFairfax, Virginia, 22031, United States
-
Zangmeister Cancer Center
RECRUITINGColumbus, Ohio, 43219, United States
Conditions
Explore the condition pages connected to this study.